Broker Recommendations
Liberum expects weak performance from WPP, lowers target price
Analysts at Liberum took a fresh look at WPP ahead of the advertising and public relations outfit's full-year results on Friday, reiterating their 'buy' rating on its stock as it noted that the group's most pressing concerns appeared to already be priced in.
Shore Capital reiterates 'sell' rating on 'sub-scale' AO World
Analysts at Shore Capital reiterated their 'sell' rating on household appliances and electricals retailer AO World on Thursday, with the broker stating the UK electrical market had become even more competitive since the group's IPO back in 2014.
Positive near-term catalysts for Rio Tinto limited, says BoA Merrill Lynch
Bank of America Merrill Lynch cut its stance on miner Rio Tinto to 'underperform' from 'neutral' on Thursday, slashing the price target to 4,150p from 4,770p as it noted limited positive catalysts in the near term.
UK miners looking overbought, telecoms very oversold - Morgan Stanley
The mining sector is starting to look overbought, according to Morgan Stanley, following a bumper quarter.
Broker tips: Marks & Spencer, Ocado, Tullow Oil, Shell
Analysts think that Marks & Spencer’s £750m joint venture with Ocado faces a lengthy period of unprofitable development, but the expense should eventually pay off.
RBC downgrades Shell to 'sector perform'
Analysts at RBC Capital Markets downgraded oil giant Shell to 'sector perform' on Wednesday, citing three key reasons for the move.
Bumpy road ahead for M&S-Ocado joint venture, analysts predict
Analysts think that Marks & Spencer’s £750m joint venture with Ocado faces a lengthy period of unprofitable development, but the expense should eventually pay off.
Wednesday broker round-up
Tullow Oil: Jefferies downgrades to hold with a target price of 222p.
Jefferies downgrades Tullow to 'hold'
Jefferies downgraded Tullow Oil to ‘hold’ from ‘buy’ on Wednesday, with the stock in sight of its new 245p price target, which was reduced from 250p, as it said "the story needs a new chapter".
RBC initiates coverage on IG Group at 'outperform'
RBC Capital Markets initiated coverage on UK-based trading outfit IG Group at 'outperform' on Tuesday despite noting that the firm's "robust growth trajectory" had been interrupted by the implementation of new EU regulatory measures.
Caterpillar hit with double-downgrade by analysts at UBS
Caterpillar shares fell at the open following a double-downgrade to 'sell' by analysts over at UBS.
Berenberg drops BT to 'hold' on dividend concerns
Analysts at Berenberg downgraded UK telecoms giant BT to 'hold' on Tuesday as it questioned whether the group's normalised free cash flow would be enough for it to meet its strategic targets while maintaining its dividend payout.
Shore Capital impressed with ABF's 'solid update'
Analysts at Shore Capital were impressed with Primark owner Associated British Foods' "solid" trading in the 24 weeks to 2 March.
NSF offer 'best rescue' for Provident Financial, says Canaccord
Canaccord Genuity upped its stance on doorstep lender Provident Financial to 'hold' from 'sell' and lifted the price target to 595p from 426p on Monday following the unsolicited £1. 3bn offer from smaller rival Non-Standard Finance.
Pearson profits set to drop next year, says Berenberg
Shares in publisher Pearson were under the cosh on Monday as Berenberg said the company was "far from a turnaround" and profits are likely to decline in 2020.
Cyclicals to stay in the lead, but mind the Greenback, JP Morgan says
Strategists at JP Morgan made the case for being positioned in Cyclicals, contrary to what 'bears' were recommending given the late stage of the economic cycle, arguing that the Federal Reserve, the US central bank, was set to 'fall behind the curve'.
JPMorgan ups target price on 'undervalued' Anglo American, names miner 'top pick'
Analysts at JPMorgan Cazenove upped their target price on multinational mining outfit Anglo American on Friday as it highlighted the group's ability to deliver a stellar combination of capital returns and growth.
GSK 'likely' to face HIV sales slowdown, UBS downgrades
UBS thinks GSK shares will struggle to perform in the near-term if there is nervousness around its ViiV HIV business.